Docs: Tesla sent Swedish and Dutch regulators Full Self-Driving safety data that traffic-safety researchers called misleading; Dutch RDW approved FSD in April
Context & Ripple Effects
The related coverage traces a rapid shift from Tesla’s announcement of Dutch approval in April to reporting in May that former labelers described extensive hazard mapping and that researchers disputed Tesla’s safety methodology. The newly disclosed regulatory materials put those earlier questions closer to the approval process itself.
That matters because the Dutch approval was presented as Tesla’s first European regulatory sign-off for the feature; the documents create a test of how regulators assess manufacturer-provided safety evidence.
First-order effects
- Tesla and the Dutch RDW face immediate scrutiny over the safety data used in the approval process, while Swedish regulators may face similar questions about the material they received.
- Researchers’ criticism weakens the evidentiary credibility of Tesla’s safety claims even though the reported approval remains in place.
Second-order effects
- Other European authorities considering FSD will have reason to examine Tesla’s methodology, underlying data and operational assumptions more closely rather than treating the Dutch decision as a simple precedent.
- The dispute increases pressure for clearer separation between reported safety outcomes, the conditions in which the system operates, and the human or mapping work supporting its performance.
Third-order effects
- If regulators increasingly require independently reviewable evidence for driver-assistance approvals, commercial deployment may depend less on manufacturer safety summaries and more on standardized audit and disclosure processes.
- The episode points to a broader governance challenge for automated-driving software: approvals can become contested when safety claims, operational design details and post-deployment evidence are not evaluated transparently.
The trend: European deployment of advanced driving software is moving from milestone approvals toward tougher scrutiny of the evidence and methods behind manufacturers’ safety claims.